GSK Surges 8% After Bumping Its 2031 Outlook To North Of $50 Billion
GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...
The GSK share price jumps 6% on positive FY 2024 results. Is it a stock to consider now?
Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.
GSK shares leap 5% as results top forecasts and guidance is upgraded! Can they keep rising?
Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains. The post ...
FTSE 100 Live 05 February: GSK shares surge on new guidance, gold at record price
An improved long-term sales target today revitalised GSK shares after their dismal 2024. The confidence in GSK’s drugs ...
Earnings dominate sentiment, as GSK shines, and Google dives
As we mentioned on Tuesday, the majority of companies on the S&P 500 that have reported earnings, have beaten estimates, and ...
Investing14h
FTSE 100 Live: GSK leads gains; Gold smashes record on Trump trade spat
Banco Santander (BME: SAN) shares spiked over 6% on Wednesday after the lender unveiled plans for €10 billion (£8.3 billion) ...
LONDON MARKET MIDDAY: FTSE 100 edges up, gold gleams and GSK shines
Stock prices in London were mixed on Wednesday afternoon, with a share price rise for GSK supporting the FTSE 100, though tariff worries continue to hang over equities. The FTSE 100 index rose 12.01 ...
pharmaphorum3d
Five lessons from GSK in social media
A recent example of content that inspired a positive response was the profiling of women in management within GSK, to mark International Women's Day which took place on 8th March. The theme of ...
pharmaphorum4d
Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancer
GlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid suggestions it had paid too much. Now, a positive phase 3 trial for the drug will ...